Esaxerenone Has Good Safety and Efficacy Profiles in Patients with Hypertension and Primary Aldosteronism, Study Reveals

A recent study in Japan has revealed that Esaxerenone – a novel nonsteroidal mineralocorticoid receptor (MR) blocker, has good safety and efficacy profiles in patients with hypertension and primary aldosteronism (PA).

Photo: Hypertension with Primary Aldosteronism | InStyleHealth


Researchers facilitated a multicenter, open-label study involving 44 patients with average age of 49 years, where 56.8% were women with hypertension and PA. Esaxerenone was administered for 12 weeks at a starting dose of 2.5 mg/day, increasing to 5 mg/day during weeks 2 or 4, according on patient response. Primary efficacy result was the change in sitting systolic (SBP) and diastolic (DBP) blood pressure.

What is primary aldosteronism?

Primary aldosteronism is defined as a hormonal disorder which leads to high blood pressure or hypertension. This occurs when the adrenal glands overproduce a hormone called aldosterone.

Average sitting SBP was 154 mm/Hg at baseline, which plummeted to 136.4 mm/Hg at the end of medication. DBP, similarly, revealed a declining trend, decreasing from 100 to 90 mm/Hg. With such reductions became apparent as early as week 2 and continued until week 8, after which changes remained stable until the end of trial period.

Close to half (47.7%) of the total participants achieved a sitting BP of <140/90 mm/Hg at the end of the medication.

Regarding safety, the experts documented treatment-emergent adverse events in 27 of the patients, generating an overall rate of 61.4%. The side effects deemed related to the test treatment were reported in 25% of patients. Although there was one serious event that was recorded, but it was not considered correlated to esaxerenone.

There were two patients who discontinued medication due to adverse events; no mortality events occurred.

The researchers said that the study is the first to investigate the antihypertensive effects of a novel MR blocker, esaxerenone, in hypertensive patients diagnosed with PA. Esaxerenone had a clinically significant antihypertensive effect in Japanese hypertensive patients with PA and was well tolerated, with consistent efficacy across a range of patient subgroups. For a full view of the clinical research, click here.

 

Source: Hypertens Res 2021;44:464-472

If you have any suggestions, please let us know.

Post a Comment (0)
Previous Post Next Post